We have fully set up and characterized a syngeneic Lewis LLC1 mouse model for preclinical studies of novel therapeutic agents and anti-cancer strategies.
In a recent collaborative work (1) supervised by Pr A. Italiano and published in Nature Cancer (2), we highlighted that the presence of mature tertiary lymphoid structures (mTLS) – a structure of prominent B cell follicles and follicular dendritic cells adjoined to a CD4/CD8 T cell-containing zone - is a new predictive biomarker for response for immune checkpoint blockers.
Read our latest publication, titled Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1.
Read our latest publication, titled Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE)
Read our latest paper, titled Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
To assess whether or not the tumor immune contexture was predictive of response to the Avelumab-Regorafenib combination regimen, Explicyte developed and ran a multiplexed immunohistofluorescence panel, in addition to Dapi.
It becomes primordial to benefit from a technological platform that allows to deal with the tumor biology complexity/heterogeneity and get specific investigations in compartments of interest (e.g. tumor vs stroma). Thanks to the GeoMx platform (Nanostring Inc.), the Digital Spatial Profiling revolution has started.
To deal with the current challenge of a qualitative and quantitative tumor immune landscape characterization, we have set up a fully integrated platform spanning from FFPE slide preparation and staining, to image digitization and analysis.
Explicyte will be attending the AACR Virtual Annual Meeting 2020 and will present new results from its collaborative work with Domain Therapeutics on the GPCRome modulation in the context of cancer immunotherapy.
Anti-angiogenic therapy combination with hypoxia-regulating agent leads to improved tumor regression
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.